Search Result

Results for "

radiolabeled

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Amino Acid Derivatives (1) Apoptosis (2) Biochemical Assay Reagents (10) Bombesin Receptor (1) Cannabinoid Receptor (1) Carbonic Anhydrase (1) CCR (1) CXCR (1) Dopamine Receptor (1) Drug Intermediate (1) Drug Metabolite (1) EGFR (1) Endogenous Metabolite (3) Endothelin Receptor (1) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (2) Fluorescent Dye (1) Glucocorticoid Receptor (2) HDAC (1) Herbicide (2) iGluR (1) Integrin (1) Ligands for Target Protein for PROTAC (1) LPL Receptor (1) mAChR (1) Melanocortin Receptor (1) Microtubule/Tubulin (1) nAChR (1) Organoid (1) PARP (2) PD-1/PD-L1 (2) PSMA (2) Radionuclide-Drug Conjugates (RDCs) (11) Ser/Thr Protease (1) Somatostatin Receptor (1) Tau Protein (1) TGF-beta/Smad (1)
By Research Areas:	Cancer (32) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (7)

By Targets:

5-HT Receptor (2)

Amino Acid Derivatives (1)

Apoptosis (2)

Biochemical Assay Reagents (10)

Bombesin Receptor (1)

Cannabinoid Receptor (1)

Carbonic Anhydrase (1)

CCR (1)

CXCR (1)

Dopamine Receptor (1)

Drug Intermediate (1)

Drug Metabolite (1)

EGFR (1)

Endogenous Metabolite (3)

Endothelin Receptor (1)

Epigenetic Reader Domain (1)

Estrogen Receptor/ERR (2)

Fluorescent Dye (1)

Glucocorticoid Receptor (2)

HDAC (1)

Herbicide (2)

iGluR (1)

Integrin (1)

Ligands for Target Protein for PROTAC (1)

LPL Receptor (1)

mAChR (1)

Melanocortin Receptor (1)

Microtubule/Tubulin (1)

nAChR (1)

Organoid (1)

PARP (2)

PD-1/PD-L1 (2)

PSMA (2)

Radionuclide-Drug Conjugates (RDCs) (11)

Ser/Thr Protease (1)

Somatostatin Receptor (1)

Tau Protein (1)

TGF-beta/Smad (1)

By Research Areas:

Cancer (32)

Cardiovascular Disease (2)

Endocrinology (1)

Inflammation/Immunology (5)

Metabolic Disease (3)

Neurological Disease (7)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W539893

NODAGA-tris(t-Bu ester) NODAG	Biochemical Assay Reagents	Cancer
NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-N6793

Phomopsin A	Microtubule/Tubulin	Cancer
Phomopsin A is a cyclic hexapeptide mycotoxin isolated from the fungus Phomopsis leptostomiformis. Phomopsin A is a noncompetitive inhibitor of the binding of radiolabeled vincristine to tubulin .

HY-101178

L-689560	iGluR	Neurological Disease
L-689560 is a potent N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site. L-689560 is widely used as a radiolabeled ligand in binding studies and used for study the roles of NMDA receptors in normal neurological processes as well as in diseases .

HY-76573

ML-10	Apoptosis	Cardiovascular Disease Cancer
ML-10 is a small molecule apoptosis probe. Due to the presence of fluorine atoms, ML-10 can be radiolabeled with ¹⁸F isotopes and can be used for apoptosis positron emission tomography imaging studies. ML-10 is selectively taken up and accumulated in apoptotic cells, while being excluded from live or necrotic cells. In addition, the uptake of ML-10 is associated with apoptotic features such as caspase activation, Annexin-V binding, and disruption of mitochondrial membrane potential .

HY-101183

THK5351	Tau Protein	Neurological Disease
THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.

HY-122939

MAIPGG	Radionuclide-Drug Conjugates (RDCs)	Cancer
MAIPGG is a bifunctional chelator and an intermediate in the synthesis of radionuclide drug conjugates (RDCs). MAIPGG can be for the radiolabeling of a variety of monoclonal antibodies with ^99mTc or ¹⁸⁶Re, which then can be used for radioimmunodetection and radioimmunotherapy of cancer .

HY-W755222

(S)-NODAGA-tris(t-Bu ester) (S)-NODAG	Biochemical Assay Reagents	Cancer
(S)-NODAGA-tris(t-Bu ester) ((S)-NODAG) is a NODAGA derivative. (S)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-W591317

(R)-NODAGA-tris(t-Bu ester) (R)-NODAG	Radionuclide-Drug Conjugates (RDCs)	Cancer
(R)-NODAGA-tris(t-Bu ester) ((R)-NODAG) is a NODAGA derivative. (R)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-169868

NOTA-FAPI-52	Biochemical Assay Reagents	Cancer
NOTA-FAPI-52 is a tracer with potent tumor uptake. NOTA-FAPI-52 can be radiolabeled to enable PET imaging or other bioimaging techniques. NOTA-FAPI-52 can be used to study diseases in which fibroblast activation protein (FAP) is overexpressed .

HY-164083

GR65630	5-HT Receptor	Neurological Disease
GR65630 is a potent and selective 5-hydroxytryptamine (5-HT) type 3 receptor antagonist. GR65630 can be used to study the expression patterns of 5-HT3 receptors in different brain regions and their possible functions in the central nervous system. GR65630 and its radiolabeled form [ ³H]GR65630 can be used to study the distribution, density and affinity of the receptors .

HY-121011

Cannabigerorcin	Cannabinoid Receptor
Cannabigerorcin is a phenolic compound found in cannabis plants, featuring a diphenol backbone and a terpene side chain. By reacting with radiolabeled methylmagnesium carbonate (MMC), its carboxyl group can be ¹⁴C-labeled. Radiolabeled Cannabigerorcin is widely used in research on cannabinoid biosynthesis pathways and metabolic processes .

HY-120947

AV-105	Drug Intermediate	Neurological Disease
AV-105 is a Florbetapir ( ¹⁸F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize ¹⁸F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .

HY-135641

Biotin-probe 1	Fluorescent Dye	Others
Biotin-probe 1 is a non-radiolabeled probe. Biotin-labeled probes can be applied to in situ hybridization .

HY-P10137

Satoreotide JR11	Somatostatin Receptor	Cancer
Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing .

HY-W097054

Fmoc-L-cysteic acid	Amino Acid Derivatives	Others
Fmoc-L-cysteic acid is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize triarylsulfonium compounds for radiolabeling of peptides .

HY-159738

N-(2-(Diethylamino)ethyl)-2-iodobenzamide	Others	Cancer
N-(2-(Diethylamino)ethyl)-2-iodobenzamide can be radiolabeled and used for melanoma imaging .

HY-W087028

NOTA-NHS ester	Radionuclide-Drug Conjugates (RDCs)	Cancer
NOTA-NHS ester is a molecule related to radiolabeling drugs (RDC) that can be used for fluorescent labeling and radioactive nuclide labeling applications .

HY-118852

Isoxaben	Herbicide	Others
Isoxaben, a herbicide, inhibits incorporation of radiolabeled glucose into an acid insoluble cell wall fraction. Isoxaben is also a specific inhibitor of cell wall biosynthesis .

HY-131009

Fluorescein-NAD+	PARP	Others
Fluorescein-NAD+ is an alternative to radiolabeled NAD and a substrate for ADP-ribosylation. Fluorescein-NAD+ can be used in PARP assays by fluorescence microscopy. Extinction Coefficient: 262 nm.

HY-137391

2-Bromoestradiol	Estrogen Receptor/ERR	Metabolic Disease
2-Bromoestradiol is a estrogen 2-hydroxylase inhibitor. 2-Bromoestradiol decreases irreversible binding of radiolabeled estradiol metabolite(s) to microsomal proteins .

HY-164574

BCN-DOTA	Radionuclide-Drug Conjugates (RDCs)	Cancer
BCN-DOTA is a cyclooctyne-linked DOTA chelator that can be radiolabeled with zirconium-89 as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells, or tissues.

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-134391

6-Phe-ADP	Biochemical Assay Reagents	Others
6-Phe-ADP is an ATP analog used as a precursor to prepare the corresponding radiolabeled triphosphate for chemical genetics approaches to study substrate specificity and catalytic efficiency of protein kinases .

HY-121470

Vesamicol	mAChR	Others
Vesamicol is a compound used to synthesize radiolabeled derivatives that can be used as sigma receptor ligands for tumor targeting inhibition and have shown certain potential in cellular uptake, biodistribution and inhibition experiments.

HY-N7755

Estradiol 3-(β-D-Glucuronide) (sodium)	Estrogen Receptor/ERR	Cancer
Estradiol 3-(β-D-Glucuronide) sodium is the glucuronic acid derivative of estradiol (HY-B0141). Estradiol 3-(β-D-Glucuronide) sodium is radiolabeled for use in tumor imaging and biodistribution studies .

HY-136201

Sodium Glucoheptonate	Biochemical Assay Reagents	Cancer
Sodium Glucoheptonate is used as a kit for radio-labeling with Tc-99m. Tc-99m glucoheptonate is kidney- and brain-imaging agent, and can be used in brain-tumor detection .

HY-118852R

Isoxaben (Standard)	Herbicide	Others
Isoxaben (Standard) is the analytical standard of Isoxaben. This product is intended for research and analytical applications. Isoxaben, a herbicide, inhibits incorporation of radiolabeled glucose into an acid insoluble cell wall fraction. Isoxaben is also a specific inhibitor of cell wall biosynthesis .

HY-118836

GSK215083	5-HT Receptor	Others
GSK215083 is a high affinity 5-HT6 receptor antagonist. GSK215083 can serves as a promising 5-HT6 radioligand candidate by radiolabeled with (11)C via methylation .

HY-P1264F

α-Bungarotoxin, FITC labeled	nAChR	Neurological Disease
α-Bungarotoxin, FITC labeledis the FITC labelled α-Bungarotoxin (HY-P1264). α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs) .

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-W088413A

DOTA-amide dihydrate	Biochemical Assay Reagents	Cancer
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Endogenous Metabolite	Cancer
Gemcitabine triphosphate (trisodium) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .

HY-17026A

Gemcitabine triphosphate dFdCTP	Drug Metabolite Endogenous Metabolite	Cancer
Gemcitabine triphosphate (dFdCTP) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .

HY-155470

IMP 243	Biochemical Assay Reagents	Cancer
IMP 243 is a symmetric di-HSG (histamine-succinyl-glycine) bivalent hapten containing a Tscg-Cys ligand and two HSG groups. IMP 243 can be radiolabeled with ^99mTc-pertechnetate. IMP 243 can be conjugated to other peptides to design bispecific antibodies (bsMAbs) for cancer research .

HY-162343

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC₅₀ value of 10.2 nM .

HY-P4681

(Phe2,Nle4)-ACTH (1-24) (human, bovine, rat)	Melanocortin Receptor	Metabolic Disease
(Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) is a fragment of the ACTH hormone. (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) can be labeled with I125 on Tyr23 to produce a radiolabeled ligand .

HY-100675

JTE-013 5 Publications Verification	LPL Receptor Apoptosis	Cancer
JTE-013 is a potent and specific S1P₂ (Sphingosine-1-Phosphate 2; EDG-5) antagonist. JTE-013 inhibits the specific binding of radiolabeled S1P to human and rat S1P₂ with IC₅₀s of 17 nM and 22 nM, respectively .

HY-B1684

Mebrofenin SQ 26962	Biochemical Assay Reagents	Others
Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function .

HY-B0727

Betamethasone valerate Betamethasone 17-valerate	Glucocorticoid Receptor	Inflammation/Immunology
Betamethasone valerate (Betamethasone 17-valerate), the 17-valerate ester of Betamethasone, is a topical corticosteroid with anti-inflammatory activity. Betamethasone valerate is used in the treatment of recurrent aphthous stomatitis. Betamethasone valerate inhibits the binding of the radiolabeled glucocorticoid dexamethasone ( ³H dexamethasone) to human epidermis and mouse skin with IC₅₀s of 5 and 6 nM, respectively .

HY-149766

PB94	HDAC	Neurological Disease
PB94 is a selective HDAC11 inhibitor (IC₅₀=108 nM). PB94 can be radiolabeled as [11C]-PB94 for use in positron emission tomography (PET), as well as brain uptake and metabolic properties in administered live animals. PB94 improves neuropathic pain in mice and could be used to study neurological indications .

HY-75706

N-Descyclopropanecarbaldehyde Olaparib	PARP Ligands for Target Protein for PROTAC	Cancer
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .

HY-15404

Darusentan Lu-135252	Endothelin Receptor	Cardiovascular Disease Endocrinology
Darusentan (Lu-135252) is a selective endothelin receptor A (ET-A) receptor antagonist, which binds with a K_i of 1.4 nM to the ET-A receptor and a K_i of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors . Darusentan competes for radiolabeled endothelin binding in rat aortic vascular smooth muscle cells (RAVSMs) membranes with single-site kinetics, exhibiting a K_i of 13 nM .

HY-159602

BET BD2-IN-3	Epigenetic Reader Domain	Cancer
BET BD2-IN-3 (compound I-58) is an inhibitor of BET, targeting the BD2 domain of BET. BET BD2-IN-3 can be radiolabeled with [11C] for positron emission tomography (PET) imaging. BET [11C]BD2-IN-3 showed suitable biodistribution in peripheral organs and tissues in PET applications in mice .

HY-W009310R

9-cis-Retinal (Standard)	Endogenous Metabolite Organoid	Others
Mebrofenin (Standard) is the analytical standard of Mebrofenin. This product is intended for research and analytical applications. Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function .

HY-P10743

BQ7876	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-B1684R

Mebrofenin (Standard)	Biochemical Assay Reagents	Others
Mebrofenin (Standard) is the analytical standard of Mebrofenin. This product is intended for research and analytical applications. Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function .

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-beta/Smad	Metabolic Disease Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab radiolabeled with ⁸⁹Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .

HY-P5018

NOTA-AE105	Radionuclide-Drug Conjugates (RDCs) Ser/Thr Protease	Cancer
NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by ⁶⁴Cu and ⁶⁸Ga. ⁶⁸Ga-NOTA-AE105 and ⁶⁴Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation . NOTA-AE105 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-147385

CCR4 antagonist 3	CCR	Inflammation/Immunology
CCR4 antagonist 3 is a potent chemokine receptor 4 (CCR4) antagonist with an IC₅₀ value of 1.7 μM for [ ¹²⁵I]TARC (thymus and activation regulated chemokine). CCR4 antagonist 3 inhibits binding of radiolabeled TARC and macrophage-derived chemokine (MDC) to CCR4 receptors on the surface of CEM cells. CCR4 antagonist 3 also inhibits the in vitro migration of CEM cells mediated by TARC (IC50 = 6.4 μM) .

HY-B0727R

Betamethasone valerate (Standard) Betamethasone 17-valerate (Standard)	Glucocorticoid Receptor	Inflammation/Immunology
Betamethasone valerate (Standard) is the analytical standard of Betamethasone valerate. This product is intended for research and analytical applications. Betamethasone valerate (Betamethasone 17-valerate), the 17-valerate ester of Betamethasone, is a topical corticosteroid with anti-inflammatory activity. Betamethasone valerate is used in the treatment of recurrent aphthous stomatitis. Betamethasone valerate inhibits the binding of the radiolabeled glucocorticoid dexamethasone ( ³H dexamethasone) to human epidermis and mouse skin with IC₅₀s of 5 and 6 nM, respectively .

Cat. No.	Product Name	Type

HY-W539893

NODAGA-tris(t-Bu ester) NODAG	Chelators
NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-101183

THK5351	Indicators
THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.

HY-B1684

Mebrofenin SQ 26962	Indicators
Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function .

HY-141637

2-Deoxy-2-fluoro-D-glucose

1 Publications Verification

2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose

Carbohydrates

2-Deoxy-2-fluoro-D-glucose, a radiolabeled glucose analog, is commonly used in medical imaging techniques such as positron emission tomography (PET) scans. FDG has unique chemical properties that allow it to be taken up by cells that actively metabolize glucose, such as cancer cells or inflamed tissue. Once absorbed, FDG emits positrons that can be detected in 2-Deoxy-2-fluoro-D-glucose scans, producing images that highlight areas of high metabolic activity in the body. This makes it a useful tool for diagnosing and monitoring a variety of diseases, including cancer and neurological disorders.

HY-W088413A

DOTA-amide dihydrate	Chelators
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .

HY-B1684R

Mebrofenin (Standard)

Indicators

Mebrofenin (Standard) is the analytical standard of Mebrofenin. This product is intended for research and analytical applications. Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function .

Cat. No.	Product Name	Target	Research Area

HY-P10734

NODAGA-RGD	Peptides
NODAGA-RGD is a peptide that can be radiolabeled and used as a radiotracer for positron emission tomography (PET) diagnosis .

HY-P10137

Satoreotide JR11	Somatostatin Receptor	Cancer
Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing .

HY-W097054

Fmoc-L-cysteic acid	Amino Acid Derivatives	Others
Fmoc-L-cysteic acid is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize triarylsulfonium compounds for radiolabeling of peptides .

HY-P1264F

α-Bungarotoxin, FITC labeled	nAChR	Neurological Disease
α-Bungarotoxin, FITC labeledis the FITC labelled α-Bungarotoxin (HY-P1264). α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs) .

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-P5018

NOTA-AE105	Radionuclide-Drug Conjugates (RDCs) Ser/Thr Protease	Cancer
NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by ⁶⁴Cu and ⁶⁸Ga. ⁶⁸Ga-NOTA-AE105 and ⁶⁴Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation . NOTA-AE105 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-P4681

(Phe2,Nle4)-ACTH (1-24) (human, bovine, rat)	Melanocortin Receptor	Metabolic Disease
(Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) is a fragment of the ACTH hormone. (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) can be labeled with I125 on Tyr23 to produce a radiolabeled ligand .

HY-P10743

BQ7876	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10781

PSMA-D5	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PSMA-D5 has a binding affinity for PSMA with K_i of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([ ⁶⁸Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as ¹⁷⁷Lu and ²²⁵Ac. PSMA-D5 ([ ⁶⁸Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC₅₀: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from the foot-and-mouth disease virus. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130?nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

Cat. No.	Product Name	Target	Research Area